EGF induced VATPase assembly and mtorc1 activation Supplemental Information Supplemental Figure Legends Figure S1. Effect of bafilomycin on EGFinduced Akt and Erk signaling. A. Hepatocytes were treated as described in the legend of Fig. 3B. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphosphoakt (Ser473) and Akt antibody (top). Densitometric quantification was performed on immunoblotting data from at least 3 independent experiments (bottom). Bars indicate s.e.m. B. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphospho Erk1/2(Thr22/Tyr24) and Erk1/2 antibody (top). Densitometric quantification was performed on immunoblotting data of at least 3 independent experiments (bottom). Bars indicate s.e.m. Figure S2. Effect of chloroquine on EGFstimulated mtorc1, Akt and Erk activation and effect of bafilomycin and chloroquine on cell apoptosis. A. Hepatocytes were pretreated with either vehicle or 1 µm chloroquine for 3 minutes, and then incubated with 1 nm EGF for the times shown. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antibodies as indicated. The results are from a single exposed gel which was sliced to allow sidebyside comparison of the data. Data shown are representative of at least 3 independent experiments. B. Densitometric quantitation of selected results from Fig. S2A is shown. Results are means ± s.e.m. of at least 3 independent experiments. *p<.5. C. Hepatocytes were pretreated with DMSO, 1 nm bafilomycin or 1 µm chloroquine for 3 minutes, and then incubated with 1 nm EGF for the times shown. Cell lysates were subjected to SDSPAGE followed by immunoblotting with anti Caspase 3 and PARP antibody. 1
EGF induced VATPase assembly and mtorc1 activation Figure S3. Similar effect of bafilomycin on insulin and EGFstimulated mtorc1, Akt and Erk activation. Hepatocytes were pretreated with either DMSO or 1 nm bafilomycin, and then stimulated with 1 nm EGF or insulin for the times shown. Cell lysates were subjected to SDSPAGE followed by immunoblotting with the indicated antibodies. Data shown are representative of at least 3 independent experiments. Figure S4. Bafilomycin does not alter mtor and Raptor association, energy status, Akt effect on TSC2, the total intracellular amino acid concentration and leucine uptake in hepatocytes. Serum starved primary hepatocytes were preincubated with either serumfree medium or warm PBS, in the presence of DMSO or 1 nm bafilomycin for 3 minutes. A. Cells were incubated with 1 nm EGF for the times shown. Cell lysates were incubated with antimtor antibody, and the immunoprecipitates were subjected to SDS PAGE followed by immunoblotting with antimtor and raptor antibodies (top). Densitometric quantification was performed on immunoblotting data of 3 independent studies (bottom). Raptor mtor association is expressed as fold over basal in each of three independent studies.bars indicate s.e.m. B. Cells were incubated with 1 nm EGF or insulin for the times shown. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphosphoampk (Thr172) and AMPK antibody. Data are representative of 3 independent experiments. C. Cells were incubated with 1 nm EGF for the times shown. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphosphotsc2 2
EGF induced VATPase assembly and mtorc1 activation (Thr1462) and TSC2 antibody (left). Densitometric quantification was performed on immunoblotting data of at least 3 independent studies (right). Bars indicate s.e.m. D. Cells were incubated with 1 nm EGF for the times shown. Total amino acid analysis was performed by using the Lamino acid quantitation kit from Biovision. E. Cells were incubated with EGF or insulin in the presence of 3Hleucine for minutes. Leucine uptake was measured by scintillation counting. Results are means ± s.e.m. of 3 independent experiments. Figure S5. Effect of chloroquine on EGFstimulated mtorc1 in the presence of cycloheximide. Hepatocytes were pretreated with either DMSO, 1 µm chloroquine (CQ), 25 µg/ml cycloheximide (CHX) or CQ and CHX together (CQCHX) for 3 minutes, and then incubated with 1nM EGF for another 3 minutes. A. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphosphop7s6k (Thr389) and p7s6k antibody (top). Quantification was performed from 3 independent experiments. * p<.5; bars indicate s.e.m. (bottom). B. Cell lysates were subjected to SDSPAGE followed by immunoblotting with antiphospho4ebp1 (Ser65) and 4EBP1 antibody (top). Quantification was performed from 3 independent experiments. * p<.5; bars indicate s.e.m. (bottom). Figure S6. Effect of in vivo chloroquine on Rag GTPase. Animals received 1 mg/2g body weight of chloroquine by intraperitoneal injection, 2 hours and 1 hour prior to EGF stimulation. animals received a comparable volume of normal saline. Rat liver subcellular fractions were prepared as described in Experimental Procedures from rat livers at minutes after EGF (1. µg/1 g BW) or 3
EGF induced VATPase assembly and mtorc1 activation vehicle administration. Immunoblotting of RagA and RagC in rat liver endosomes (EN) is shown. 4
Supplemental Figure S1 EGF induced VATPase assembly and mtorc1 activation A EGF (min) Bafilomycin 3 6 3 6 PAkt(S473) PAKT(Ser473)/AKT(% Maximal) PAkt/Akt (% Maximal) Akt 1 Baf 8 6 4 2 1 2 3 4 5 6 Time after EGF (min) EGF (min) Bafilomycin 3 6 3 6 PErk (T22/Y24) Erk1/2 1 PErk/ErK (% Maximal) B Baf 8 6 4 2 1 2 3 4 Time after EGF 5 (min) 5 6
EGF induced VATPase assembly and mtorc1 activation Supplemental Figure S2 EGF (min) Chloroquine 3 6 3 6 PYEGFR EGFR PAkt (S473) B Pp7S6K /p7s6k(% Maximal) A Akt PAkt/Akt (% Maximal) (T22/Y24) Erk1/2 * 8 6 4 2 1 2 3 4 12 PErk 5 6 CQ 1 8 6 4 2 Actin p7s6k EGF (min) 2 6 P4EBP1 PErk/Erk (% Maximal) Pp7S6K (T389) Chloroquine CQ 1 1 2 3 4 4EBP1 6 6 1 8 6 4 2 1 2 3 4 Time After EGF (min) (S65) 5 5 6
C EGF induced VATPase assembly and mtorc1 activation Bafilomycin Chloroquine EGF (min) 3 6 3 6 37 3 6 Caspase 3 3 25 2 PARP 116 89 24 7
EGF induced VATPase assembly and mtorc1 activation Supplemental Figure S3 5min min EGF Ins EGF 3min 6min Ins EGF Ins EGF Ins Bafilomycin Pp7S6K (T389) p7s6k 4EBP1 mtor PErk (T22/Y24) PAkt (S473) PYEGFR PYIR 8
Supplemental Figure S4 A EGF (min) 2 5 PBS WB:Raptor WB:mTOR Raptor/mTOR (fold basal) IP:mTOR Bafilomycin EGF induced VATPase assembly and mtorc1 activation 1.5 DMSO Baf 1.5 2 PBS EGF Insulin Time after EGF (min) 2min 5min Insulin EGF Insulin EGF B Bafilomycin 5 min PBS PAMPK (T172) AMPK 12 EGF (min) 3 PTSC2 / TSC2(% Maximal) C Bafilomycin 3 Baf 1 PTSC2 (T1462) TSC2 control 9 8 6 4 2 Time after EGF (min) 3
Free Amino Acid (nmol/1 6 cells) D 45 4 35 3 25 2 1 5 EGF induced VATPase assembly and mtorc1 activation Baf 5 6 Time after EGF (min) E 3 HLeucine uptake (Fold PBSstarved) 1.6 1.4 1.2 1.8.6.4.2 DMSO Baf Ins EGF PBS Starved 1
Supplemental Figure S5 EGF induced VATPase assembly and mtorc1 activation A EGF Pp7S6K (T389) p7s6k CQ CHX CQCHX Pp7S6K/p7S6K (% Maximal) 12 1 8 6 4 2 Basal EGF CQ CHX CQCHX * B EGF P4EBP1 (S65) 4EBP1 CQ CHX CQCHX P4EBP1/4EBP1(% Maximal) * 11
Supplemental Figure S6 EGF induced VATPase assembly and mtorc1 activation EGF Chloroquine RagA(EN) EGF Chloroquine RagC(EN) 12
EGF induced VATPase assembly and mtorc1 activation Table S1 Functional categorization of the proteins changing in ENDRMs following EGF determined by proteomic analysis. Protein Category # of proteins % of total # of proteins # of proteins Signaling 34 7.7 26 8 Receptor and Transporter 57 12.9 41 16 Trafficking 73 16.5 53 2 Transcription/Translation 16 3.6 9 7 Ubiquitination/ Proteasome 8 1.8 6 2 Structural/Cytoskeleton 22 5. 18 4 Metabolism 57 12.9 33 24 Unknown Function 86 19.5 67 19 Miscellaneous 89 2.1 39 5 Total 442 1 292 Proteins from ENDRM fractions prepared from the livers of 3 control and 3 EGFtreated rats were identified by proteomic analysis as described in Experimental Procedures. The proteins listed per category were those which changed by >1.5 fold increase or decrease in mean peptide counts in all 3 EGFtreated animals., increased post EGF;, decreased post EGF. 13
EGF induced VATPase assembly and mtorc1 activation Table S2 Concentrations of amino acids (AAs) in medium and primary hepatocytes (nmol/ml) before and after treatment with EGF and bafilomycin (Baf). Medium Hepatocytes a Basal EGF AA Baf Baf % change Essential MET 449.8 49.5±1.3 53.8±6.4 19.±1.8 65%** VAL 1.6 18.8±.5 2.3±2.6 7.8±1.4 62%** PHE 624.2 37.5±.8 44.8±3.1 21.4±2.3 52%** ILE 451.1 3.1±.5 33.3±3.5 17.±2. 49%** LEU 214.9 27.2±.8 29.2±3.1.3±1.3 48%** LYS 4.5 14.4±.2 16.±1.6 9.±1. 44%** THR 449.1 35.8±.5 41.2±4.2 37.5±3.5 n/s TRP 44.1 4.8±.1 5.1±.6 3.8±.6 n/s ARG b 7.2 28.6±1. 33.7±2.8 13.8±2.5 59%** TYR b 212.4 26.7±.5 29.±3..9±1.7 45%** HIS b.3 12.7±.8 13.4±2.3 14.3±3.4 n/s SUM 2764.3 267.1±6.5 299.6±3.6 167.1±19.9 46%** Nonessential ORN 29.±1.2 32.3±.9 25.4±1.8 21%* ASN 99.2 13.9±.1.1±1.5 9.9±1.2 35%* ASP 23.9±.4 24.±1.8 38.6±3.9 61%* TAU 6.5±.3 7.±.8 12.6±1. 8%** GLU 5. 53.5±2.6 62.1±5.1 74.8±3.1 n/s SER 249.8 54.6±1. 6.3±6. 41.3±3.7 n/s GLN 2497.5 73.6±.6 8.2±8. 8.9±5.4 n/s GLY 249.8 47.6±4.4 47.6±5.2 54.4±5.7 n/s ALA 5. 55.1±.6 58.5±3.3 48.9±4.3 n/s CIT 2.7±.3 3.±.2 3.8±.6 n/s SUM 4259. 36.2±11.5 39.1±32.7 39.5±3.6 n/s TOTAL 723.3 627.3±18. 689.7±63.3 557.5±5.5 n/s a The values in the table are means of 3 independent replicates ±s.e.m. *p<.5, **p<.1. b Essential only in certain cases. 14
EGF induced VATPase assembly and mtorc1 activation Table S3 Concentrations of amino acids (AAs) in primary hepatocytes (nmol/ml) after treatment with EGF with bafilomycin (Baf) and cycloheximide (CHX). AA Baf CHX BafCHX Essential LEU 53.8±4.5 26.5±1.7 67.2±5.1 41.4±1.1 MET 22.6±1.7 14.3±.9 25.2±2.1 19.8±.5 LYS 41.1±3.5 25.1±1.5 51.6±3.9 38.3±.9 VAL 37.3±3.2 23.6±1.4 45.±2.8 33.7±.7 PHE 3.2±2. 18.±.9 32.±2.6 24.3±.8 ILE 16.8±1.4 1.6±.6 19.8±1.3 14.4±.3 THR 47.1±3.1 43.4±2.5 6.8±2.8 57.7±1.3 TRP 6.5±.3 5.±.2 6.7±.5 6.1±.2 ARG a 26.9±1.7.5±.5 33.±3.4 22.7±1.3 TYR a 27.4±1.5 16.4±.8 29.6±2.7 22.2±.4 HIS a 16.9±1.2 13.2±1.2 17.±1.1 16.±.3 SUM 326.6±22.6 211.6±11.2 387.9±27.5 296.4±6.8 NonEssential ORN 3.9±1.8 27.1±1.9 37.8±2.5 36.3±.6 ASN 16.6±1.2 12.2±.7 2.3±1.2 16.1±.2 ASP 25.1±1.5 36.6±2.3 27.1±1.4 4.1±.6 TAU 12.4±.8 14.±1.4 12.2±.6 14.2±.3 GLU 71.3±1.7 8.±3. 73.2±4.4 86.6±2.9 SER 79.8±4.8 65.7±3.2 95.3±5.2 87.1±2.1 GLN 16.±3. 165.5±6.3 163.7±9.6 178.5±4.3 GLY 45.6±2.4 46.4±2.6 59.4±7.5 66.1±12. ALA 58.9±1.2 52.4±1.9 63.±4. 62.4±1.7 CIT 5.±.2 6.8±.1 5.7±.4 7.5±.4 SUM 55.6±18.3 56.6±21.8 557.8±35.8 594.7±1.6 TOTAL 832.1±37.8 718.1±32.9 945.7±62.9 891.1±11.2 a Essential only in certain cases The values in the table are means of 3 independent replicates ±s.e.m.